Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
grade F 74.03 -1.50% -1.13
GILD closed down 3.43 percent on Monday, June 1, 2020, on 73 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Jun 19
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical GILD trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -1.50%
Fell Below 50 DMA Bearish -1.50%
Cup with Handle Other -1.50%
Crossed Above 20 DMA Bullish -4.88%
Crossed Above 50 DMA Bullish -4.88%
Expansion Pivot Buy Setup Bullish Swing Setup -4.88%
Pocket Pivot Bullish Swing Setup -4.88%
Outside Day Range Expansion -4.88%
Up 3 Days in a Row Strength -4.88%
Shooting Star Candlestick Bearish -1.71%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Medicine Chemistry Biopharmaceutical Diseases Infection Coronavirus Organic Chemistry Cystic Fibrosis Pulmonary Arterial Hypertension Cardiovascular Diseases HIV Hepatotoxins Respiratory Diseases Gilead Sciences Liver Disease Prodrugs AIDS Cytomegalovirus Retinitis Fungal Infections Tenofovir Disoproxil

Is GILD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 85.97
52 Week Low 60.89
Average Volume 20,185,251
200-Day Moving Average 68.81
50-Day Moving Average 76.66
20-Day Moving Average 76.27
10-Day Moving Average 74.42
Average True Range 2.73
ADX 10.37
+DI 21.68
-DI 17.74
Chandelier Exit (Long, 3 ATRs ) 77.48
Chandelier Exit (Short, 3 ATRs ) 80.49
Upper Bollinger Band 80.94
Lower Bollinger Band 71.59
Percent B (%b) 0.38
BandWidth 12.26
MACD Line -0.69
MACD Signal Line -0.67
MACD Histogram -0.0162
Fundamentals Value
Market Cap 98.16 Billion
Num Shares 1.31 Billion
EPS 9.21
Price-to-Earnings (P/E) Ratio 8.16
Price-to-Sales 3.57
Price-to-Book 4.49
PEG Ratio -1.08
Dividend 2.08
Dividend Yield 2.77%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 78.94
Resistance 3 (R3) 79.10 78.00 78.31
Resistance 2 (R2) 78.00 77.04 77.92 78.10
Resistance 1 (R1) 76.58 76.44 76.03 76.42 77.89
Pivot Point 75.48 75.48 75.21 75.40 75.48
Support 1 (S1) 74.06 74.52 73.51 73.90 72.43
Support 2 (S2) 72.96 73.92 72.88 72.22
Support 3 (S3) 71.54 72.96 72.01
Support 4 (S4) 71.38